These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 24374223)

  • 1. NanoCluster budesonide formulations enable efficient drug delivery driven by mechanical ventilation.
    Pornputtapitak W; El-Gendy N; Mermis J; O'Brien-Ladner A; Berkland C
    Int J Pharm; 2014 Feb; 462(1-2):19-28. PubMed ID: 24374223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanocluster budesonide formulations enhance drug delivery through endotracheal tubes.
    Pornputtapitak W; El-Gendy N; Berkland C
    J Pharm Sci; 2012 Mar; 101(3):1063-72. PubMed ID: 22095757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of budesonide nanocluster dry powder aerosols: formulation and stability.
    El-Gendy N; Huang S; Selvam P; Soni P; Berkland C
    J Pharm Sci; 2012 Sep; 101(9):3445-55. PubMed ID: 22619045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of budesonide nanocluster dry powder aerosols: preformulation.
    El-Gendy N; Selvam P; Soni P; Berkland C
    J Pharm Sci; 2012 Sep; 101(9):3434-44. PubMed ID: 22623018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of budesonide nanocluster dry powder aerosols: processing.
    El-Gendy N; Selvam P; Soni P; Berkland C
    J Pharm Sci; 2012 Sep; 101(9):3425-33. PubMed ID: 22539360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dry powder inhaler with reduced mouth-throat deposition.
    Wang ZL; Grgic B; Finlay WH
    J Aerosol Med; 2006; 19(2):168-74. PubMed ID: 16796541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SCF-engineered powders for delivery of budesonide from passive DPI devices.
    Lobo JM; Schiavone H; Palakodaty S; York P; Clark A; Tzannis ST
    J Pharm Sci; 2005 Oct; 94(10):2276-88. PubMed ID: 16136557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coated particle assemblies for the concomitant pulmonary administration of budesonide and salbutamol sulphate.
    Raula J; Rahikkala A; Halkola T; Pessi J; Peltonen L; Hirvonen J; Järvinen K; Laaksonen T; Kauppinen EI
    Int J Pharm; 2013 Jan; 441(1-2):248-54. PubMed ID: 23200957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
    de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
    Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of aerosol generator devices at 3 locations in humidified and non-humidified circuits during adult mechanical ventilation.
    Ari A; Areabi H; Fink JB
    Respir Care; 2010 Jul; 55(7):837-44. PubMed ID: 20587094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of primary crystallisation conditions on the mechanical and interfacial properties of micronised budesonide for dry powder inhalation.
    Kubavat HA; Shur J; Ruecroft G; Hipkiss D; Price R
    Int J Pharm; 2012 Jul; 430(1-2):26-33. PubMed ID: 22449413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacoscintigraphic evaluation of lipid dry powder budesonide formulations for inhalation.
    Sebti T; Pilcer G; Van Gansbeke B; Goldman S; Michils A; Vanderbist F; Amighi K
    Eur J Pharm Biopharm; 2006 Aug; 64(1):26-32. PubMed ID: 16697169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of nebulizer type, position, and bias flow on aerosol drug delivery in simulated pediatric and adult lung models during mechanical ventilation.
    Ari A; Atalay OT; Harwood R; Sheard MM; Aljamhan EA; Fink JB
    Respir Care; 2010 Jul; 55(7):845-51. PubMed ID: 20587095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Air classifier technology (ACT) in dry powder inhalation Part 3. Design and development of an air classifier family for the Novolizer multi-dose dry powder inhaler.
    de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
    Int J Pharm; 2006 Mar; 310(1-2):72-80. PubMed ID: 16442248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of supercritical fluid engineered budesonide powder for respiratory delivery using nebulisers.
    Amani A; Chrystyn H; Clark BJ; Abdelrahim ME; York P
    J Pharm Pharmacol; 2009 Dec; 61(12):1625-30. PubMed ID: 19958584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stability and performance characteristics of a budesonide powder for inhalation with a novel dry powder inhaler device.
    Fyrnys B; Stang N; Wolf-Heuss E
    Curr Opin Pulm Med; 2001 Apr; 7 Suppl 1():S7-11. PubMed ID: 11385814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cohesive-adhesive balances in dry powder inhaler formulations II: influence on fine particle delivery characteristics.
    Begat P; Morton DA; Staniforth JN; Price R
    Pharm Res; 2004 Oct; 21(10):1826-33. PubMed ID: 15553229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variability of fine particle dose and lung deposition of budesonide delivered through two multidose dry powder inhalers.
    Munzel U; Marschall K; Fyrnys B; Wedel M
    Curr Med Res Opin; 2005 Jun; 21(6):827-33. PubMed ID: 15969882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro assessment of drug delivery through an endotracheal tube using a dry powder inhaler delivery system.
    Everard ML; Devadason SG; Le Souëf PN
    Thorax; 1996 Jan; 51(1):75-7. PubMed ID: 8658374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of some parameters influencing the drug delivery from a dry powder inhalation device using an in vitro model of the horse airways.
    Duvivier DH; Chiap P; Crommen J; Lekeux P
    Vet Res; 1997; 28(6):557-64. PubMed ID: 9428149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.